Jill Murphy


FDA grants trastuzumab deruxtecan breakthrough therapy designation for breast cancer

October 05, 2021

The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.